ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM) Article

Lassman, Andrew, Dimino, Cara, Mansukhani, Mahesh et al. (2017). ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM) . NEURO-ONCOLOGY, 19(suppl_6), vi15-vi15. 10.1093/neuonc/nox168.055

cited authors

  • Lassman, Andrew; Dimino, Cara; Mansukhani, Mahesh; Murty, Vundavalli; Ansell, Peter J; Bain, Earle; Holen, Kyle D; Roberts-Rapp, Lisa A; Lee, James; Curran, Walter; Mehta, Minesh P; Canoll, Peter

authors

publication date

  • November 6, 2017

published in

keywords

  • 3 Good Health and Well Being
  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi15

end page

  • vi15

volume

  • 19

issue

  • suppl_6